Results at 2 years of a phase IIb extension study of the exon-skipping drug eteplirsen in patients with DMD

被引：1
|
作者：
Mendell, J. R. [1 ]
Rodino-Klapac, L. [1 ]
Sahenk, Z. [1 ]
Roush, K. [1 ]
Bird, L. [1 ]
Lowes, L. P. [1 ]
Alfano, L. [1 ]
Gomez, A. M. [1 ]
Lewis, S. [1 ]
Malik, V. [1 ]
Shontz, K. [1 ]
Flanigan, K. M. [1 ]
Kean, J. R. [1 ]
Allen, H. D. [1 ]
Shilling, C. [1 ]
Sazani, P. [2 ]
Saoud, J. [2 ]
Kaye, E. M. [2 ]
机构：
[1] Nationwide Childrens Hosp, Columbus, OH USA
[2] Sarepta Therapeut, Cambridge, MA USA
来源：
NEUROMUSCULAR DISORDERS | 2013年 / 23卷 / 9-10期
关键词：
D O I：
10.1016/j.nmd.2013.06.581
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：804 / 805
页数：2
相关论文
共 50 条
  • [31] The effect of tezepelumab in patients with allergic asthma: Results from the PATHWAY phase IIb study
    Corren, J.
    Colice, G.
    Salapa, K.
    Bowen, K.
    Llanos-Ackert, J.
    ALLERGY, 2020, 75 : 19 - 19
  • [32] A Japanese phase I/II study of NS-065/NCNP-01, exon 53 skipping drug, in patients with Duchenne muscular dystrophy - a dose-finding study
    Komaki, H.
    Takeshima, Y.
    Matsumura, T.
    Ozasa, S.
    Funato, M.
    Egawa, Y.
    Takeda, S.
    NEUROMUSCULAR DISORDERS, 2018, 28 : S68 - S68
  • [33] SAFETY AND DISEASE ACTIVITY CHANGES IN AN EXTENSION OF A PHASE IIB STUDY OF ATACICEPT IN PATIENTS WITH SLE (ADDRESS II)
    Wallace, D. J.
    Isenberg, D.
    Wax, S.
    Kao, A.
    Chang, P.
    Fraser, P. A.
    Merrill, J. T.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 863 - 863
  • [34] Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study
    Sakai, Hiroshi
    Morise, Masahiro
    Kato, Terufumi
    Matsumoto, Shingo
    Sakamoto, Tomohiro
    Kumagai, Toru
    Tokito, Takaaki
    Atagi, Shinji
    Kozuki, Toshiyuki
    Tanaka, Hiroshi
    Chikamori, Kenichi
    Shinagawa, Naofumi
    Takeoka, Hiroaki
    Bruns, Rolf
    Straub, Josef
    Schumacher, Karl Maria
    Paik, Paul K.
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (08) : 1261 - 1268
  • [35] Results of a phase IIb study in recurrent or refractory glioblastoma patients with the TGF-beta-2 inhibitor AP 12009
    Hau, P.
    Bogdahn, U.
    Olyushin, V. E.
    Mahapatra, A.
    Parfenov, V. E.
    Venkataramana, K.
    Ludwig, S.
    Jachimczak, P.
    Heinrichs, H.
    Schlingensiepen, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: results from the VISION study and local UK experience
    Cui Wanyuan
    Brown, Nick
    Brown, Victoria
    Bulusu, Ramesh
    Denton, Arshi
    Evans, Joanne
    Forster, Martin
    Papadatos-Pastos, Dionysis
    Pellegrino, Loredana
    Walsh, Nessa
    Bruns, Rolf
    Otto, Gordon
    Paik, Paul
    LUNG CANCER, 2022, 165 : S38 - S39
  • [37] Targeted therapy with AP 12009 in recurrent or refractory glioblastoma patients: Results of a phase Iib study
    Bogdahn, U.
    Hau, P.
    Olyushin, V.
    Mahapatra, A. K.
    Parfenov, V.
    Venkataramana, N. K.
    Wassmann, H.
    Ludwig, S.
    Heinrichs, H.
    Schlingensiepen, K. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study
    Morise, Masahiro
    Kato, Terufumi
    Matsumoto, Shingo
    Inoue, Takako
    Sakamoto, Tomohiro
    Tokito, Takaaki
    Atagi, Shinji
    Kozuki, Toshiyuki
    Takeoka, Hiroaki
    Chikamori, Kenichi
    Shinagawa, Naofumi
    Tanaka, Hiroshi
    Horii, Eisuke
    Adrian, Svenja
    Bruns, Rolf
    Johne, Andreas
    Paik, Paul K.
    Sakai, Hiroshi
    CANCER SCIENCE, 2024, 115 (04) : 1296 - 1305
  • [39] Phase 2 Open-Label Extension Study With Donidalorsen in Patients With Hereditary Angioedema: 1 Year Versus 2 Years
    Tachdjian, Raffi
    Bordone, Laura
    Dorow, Steve
    Cohn, Danny
    Schneider, Eugene
    Deng, Yiwen
    Newman, Kenneth
    Alexander, Veronica
    Riedl, Marc
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB11 - AB11
  • [40] A Phase II Study of Tepotinib in Advanced Solid Cancers with MET exon 14 Skipping Mutation or Amplification; Results of Non-small Cell Lung Cancer
    Yang, Y.
    Kang, E. J.
    Lee, S.
    Kim, Y. J.
    Lim, S. M.
    Ahn, M. -J.
    Lee, Y. J.
    Kim, T. M.
    Kim, I.
    Ahn, H. K.
    Jeung, H. C.
    Lee, S. I.
    Oh, S. Y.
    Bae, W. K.
    Ryu, H.
    Park, K. H.
    Lee, K. H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S359 - S360
12345